Journal logo

Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size, Epidemiology, Analysis & Trends 2023-2033 | by IMARC Group

The report offers competitor analysis, regional analysis, and recent advancements in the global market. The report also highlights key segments and market drivers, as well as challenges faced by industry players.

By Frank MorganPublished 6 months ago 4 min read

The newly published report by IMARC Group, titled, ”Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033″, presents a comprehensive assessment of the chimeric antigen receptor (CAR) T-cell therapy market size. The report provides an overview of the market trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease overview, market scenario, and growth trends.

Chimeric antigen receptor (CAR) T-cell therapy represents an immunotherapy approach that has the potential to transform cancer treatment by using the immune system to fight diseases. It requires genetically engineering T cells to express a chimeric antigen receptor that targets a particular tumor antigen. These re-engineered cells are generally then multiplied and infused into the body to recognize and kill cancer cells with targeted antigens on their surface. Consequently, chimeric antigen receptor (CAR) T-cell therapy is gaining extensive traction across the globe.

Request a Free Sample Report:

Market Trend:

The rising incidences of cancer, on account of the growing utilization of tobacco products, unhealthy dietary patterns, and sedentary lifestyles of individuals, are primarily driving the chimeric antigen receptor (CAR) T-cell therapy market. Additionally, continuous improvements in the safety and efficacy of current and emerging therapies and strong drug pipelines are further catalyzing the market growth.

Besides this, the increasing number of healthcare settings that administer CAR T, the launch of favorable policies by government bodies, and the widespread adoption of anti-CD19 autologous CAR T therapy to treat individuals with relapsed or refractory acute lymphoblastic leukemia (ALL) are acting as significant growth-inducing factors. Moreover, the expanding geriatric population who are susceptible to developing advanced lymphomas and the elevating prevalence of chronic diseases are positively influencing the global market.

Apart from this, the escalating demand for regenerative medicines and numerous technological advancements in the healthcare industry are also stimulating the market growth. Furthermore, extensive R&D activities are anticipated to fuel the chimeric antigen receptor (CAR) T-cell therapy market over the forecasted period.

Report Period:

Base Year: 2022

Historical Period: 2017-2022

Market Forecast: 2023-2033

Countries Included:

United States



United Kingdom




Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the chimeric antigen receptor (CAR) T-cell therapy market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the chimeric antigen receptor (CAR) T-cell therapy market

Reimbursement scenario in the market

In-market and pipeline drugs

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Regulatory Status

Ask an Analyst for Report Customization with TOC & List of figures:

Key Questions Answered in this Report:

How has the chimeric antigen receptor (CAR) T-cell therapy market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?

What was the country-wise size of the chimeric antigen receptor (CAR) T-cell therapy market across the seven major markets in 2022 and what will it look like in 2033?

What is the growth rate of the chimeric antigen receptor (CAR) T-cell therapy market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

About Us: –

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US


134 N 4th St.

Brooklyn, NY 11249, USA

Email: [email protected]

Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800


About the Creator

Frank Morgan

Reader insights

Be the first to share your insights about this piece.

How does it work?

Add your insights


There are no comments for this story

Be the first to respond and start the conversation.

Sign in to comment

    Find us on social media

    Miscellaneous links

    • Explore
    • Contact
    • Privacy Policy
    • Terms of Use
    • Support

    © 2023 Creatd, Inc. All Rights Reserved.